PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34390745-11 2022 Due to the cancer-specific nature, LAT1 can also be used for cancer-specific delivery of anti-tumor agents such as l-para-boronophenylalanine used for boron neutron capture therapy and alpha-emitting nuclide-labeled LAT1 substrates developed for nuclear medicine treatment. 4-boronophenylalanine 115-141 solute carrier family 7 member 5 Homo sapiens 35-39 21367608-1 2011 The system L-amino acid transporter (LAT1) imports p-boronophenylalanine (BPA) mainly into proliferating cells. 4-boronophenylalanine 51-72 solute carrier family 7 member 5 Homo sapiens 37-41 21367608-1 2011 The system L-amino acid transporter (LAT1) imports p-boronophenylalanine (BPA) mainly into proliferating cells. 4-boronophenylalanine 74-77 solute carrier family 7 member 5 Homo sapiens 37-41 21367608-2 2011 This study investigates in three tumor entities whether the proportion of tumor cells expressing LAT1 and/or Ki67 correlates with BPA uptake. 4-boronophenylalanine 130-133 solute carrier family 7 member 5 Homo sapiens 97-101 19244126-1 2009 The system l-amino acid transporter-1 (LAT-1) imports p-boronophenylalanine (BPA) into cells and may play a major role in the effectiveness of BPA-based boron neutron capture therapy. 4-boronophenylalanine 54-75 solute carrier family 7 member 5 Homo sapiens 11-37 19244126-1 2009 The system l-amino acid transporter-1 (LAT-1) imports p-boronophenylalanine (BPA) into cells and may play a major role in the effectiveness of BPA-based boron neutron capture therapy. 4-boronophenylalanine 54-75 solute carrier family 7 member 5 Homo sapiens 39-44 19244126-1 2009 The system l-amino acid transporter-1 (LAT-1) imports p-boronophenylalanine (BPA) into cells and may play a major role in the effectiveness of BPA-based boron neutron capture therapy. 4-boronophenylalanine 77-80 solute carrier family 7 member 5 Homo sapiens 11-37 19244126-1 2009 The system l-amino acid transporter-1 (LAT-1) imports p-boronophenylalanine (BPA) into cells and may play a major role in the effectiveness of BPA-based boron neutron capture therapy. 4-boronophenylalanine 77-80 solute carrier family 7 member 5 Homo sapiens 39-44 19244126-1 2009 The system l-amino acid transporter-1 (LAT-1) imports p-boronophenylalanine (BPA) into cells and may play a major role in the effectiveness of BPA-based boron neutron capture therapy. 4-boronophenylalanine 143-146 solute carrier family 7 member 5 Homo sapiens 11-37 19244126-1 2009 The system l-amino acid transporter-1 (LAT-1) imports p-boronophenylalanine (BPA) into cells and may play a major role in the effectiveness of BPA-based boron neutron capture therapy. 4-boronophenylalanine 143-146 solute carrier family 7 member 5 Homo sapiens 39-44 19244126-8 2009 These LAT-1 data indicate that BPA-based boron neutron capture therapy might affect up to 70% of tumor cells, representing a three times higher proportion of tumor cells than their cell cycle status might suggest. 4-boronophenylalanine 31-34 solute carrier family 7 member 5 Homo sapiens 6-11 25580517-0 2015 Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2. 4-boronophenylalanine 0-19 solute carrier family 7 member 5 Homo sapiens 105-109 25580517-7 2015 Among aromatic amino acid transporters, ATB(0,+), LAT1 and LAT2 were found to transport BPA with Km values of 137.4 +- 11.7, 20.3 +- 0.8 and 88.3 +- 5.6 muM, respectively. 4-boronophenylalanine 88-91 solute carrier family 7 member 5 Homo sapiens 50-54 25580517-8 2015 Uptake experiments in cancer cell lines revealed that the LAT1 protein amount was the major determinant of BPA uptake at 100 muM, whereas the contribution of ATB(0,+) became significant at 1000 muM, accounting for 20-25% of the total BPA uptake in MCF-7 breast cancer cells. 4-boronophenylalanine 107-110 solute carrier family 7 member 5 Homo sapiens 58-62 25580517-9 2015 ATB(0,+), LAT1 and LAT2 transport BPA at affinities comparable with their endogenous substrates, suggesting that they could mediate effective BPA uptake in vivo. 4-boronophenylalanine 34-37 solute carrier family 7 member 5 Homo sapiens 10-14 25580517-9 2015 ATB(0,+), LAT1 and LAT2 transport BPA at affinities comparable with their endogenous substrates, suggesting that they could mediate effective BPA uptake in vivo. 4-boronophenylalanine 142-145 solute carrier family 7 member 5 Homo sapiens 10-14 25580517-10 2015 The high and low affinities of LAT1 and ATB(0,+), respectively, differentiate their roles in BPA uptake. 4-boronophenylalanine 93-96 solute carrier family 7 member 5 Homo sapiens 31-35 25580517-11 2015 ATB(0,+), as well as LAT1, could contribute significantly to the tumor accumulation of BPA at clinical dose. 4-boronophenylalanine 87-90 solute carrier family 7 member 5 Homo sapiens 21-25 32010792-1 2020 In the current clinical boron neutron capture therapy (BNCT), p-boronophenylalanine (BPA) has been the most powerful drug owing to its ability to accumulate selectively within cancers through cancer-related amino acid transporters including LAT1. 4-boronophenylalanine 62-83 solute carrier family 7 member 5 Homo sapiens 241-245 32010792-1 2020 In the current clinical boron neutron capture therapy (BNCT), p-boronophenylalanine (BPA) has been the most powerful drug owing to its ability to accumulate selectively within cancers through cancer-related amino acid transporters including LAT1. 4-boronophenylalanine 85-88 solute carrier family 7 member 5 Homo sapiens 241-245 32010792-3 2020 Here, we report that poly(vinyl alcohol) (PVA) can form complexes with BPA through reversible boronate esters in aqueous solution, and the complex termed PVA-BPA can be internalized into cancer cells through LAT1-mediated endocytosis, thereby enhancing cellular uptake and slowing the untoward efflux. 4-boronophenylalanine 158-161 solute carrier family 7 member 5 Homo sapiens 208-212 33956158-1 2021 In this study, we examined whether the cancer cell-killing effects of boron neutron capture therapy (BNCT) are enhanced by manipulating the expression levels of l-type amino acid transporter 1 (LAT1) of human cancer cells, which transports boronophenylalanine into cells. 4-boronophenylalanine 240-259 solute carrier family 7 member 5 Homo sapiens 161-192 33956158-1 2021 In this study, we examined whether the cancer cell-killing effects of boron neutron capture therapy (BNCT) are enhanced by manipulating the expression levels of l-type amino acid transporter 1 (LAT1) of human cancer cells, which transports boronophenylalanine into cells. 4-boronophenylalanine 240-259 solute carrier family 7 member 5 Homo sapiens 194-198